Early cessation and non-response are important and possibly related problems in growth hormone therapy: An OZGROW analysis

Show simple item record

dc.contributor.author Hughes, IP en
dc.contributor.author Choong, C en
dc.contributor.author Rath, S en
dc.contributor.author Atkinson, H en
dc.contributor.author Cotterill, A en
dc.contributor.author Cutfield, Wayne en
dc.contributor.author Hofman, Paul en
dc.contributor.author Harris, M en
dc.date.accessioned 2016-08-18T03:31:31Z en
dc.date.issued 2016-08 en
dc.identifier.citation Growth Hormone and IGF Research, 2016, 29, pp. 63 - 70 en
dc.identifier.issn 1532-2238 en
dc.identifier.uri http://hdl.handle.net/2292/30056 en
dc.description.abstract Objective: To investigate growth hormone (GH) treatment and treatment cessation with respect to efficacy and efficiency. To identify factors that best classify or predict cessation type: completed treatment (CT), early cessation (EC), or non-response (NR). Design: Observational study (1990-2013) of the Australian GH Program comparing CT, EC, and NR groups with respect to demographic, clinical, and response criteria. All patients treated for GH deficiency (GHD; 909), short stature and slow growth (SSSG; 2144), and Turner Syndrome (TS; 626) were included. Information was retrieved from the OZGROW database. Results: 51.9% of patients were EC, 40.7% CT and 7.4% NR.Median treatment durations for NR patients were often longer than patients who completed treatment. EC and NR groups were both associated with poor growth response with males overrepresented.Socioeconomic status differentiated NR (higher) and EC (lower) groups. Conclusions: EC was observed at very high rates and appears, generally, to be a little-recognised but frequent problem in GH therapy.EC and delayed recognition of NR may be interrelated being differentiated by the decision to cease or continue treatment following poor response.Poor treatment compliance is likely a major causal factor in EC.Strategies to address poor response and compliance have been developed, however, given the scale of these problems, it may be that long acting GH formulations or individualized treatment need consideration. en
dc.description.uri http://www.journals.elsevier.com/growth-hormone-and-igf-research/ en
dc.publisher Elsevier en
dc.relation.ispartofseries Growth Hormone and IGF Research en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/1096-6374/ en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.title Early cessation and non-response are important and possibly related problems in growth hormone therapy: An OZGROW analysis en
dc.type Journal Article en
dc.identifier.doi 10.1016/j.ghir.2016.04.006 en
pubs.begin-page 63 en
pubs.volume 29 en
dc.identifier.pmid 27179230 en
pubs.author-url http://www.growthhormoneigfresearch.com/article/S1096-6374(16)30035-1/fulltext en
pubs.end-page 70 en
pubs.publication-status Published en
dc.rights.accessrights http://purl.org/eprint/accessRights/RestrictedAccess en
pubs.subtype Article en
pubs.elements-id 529019 en
pubs.org-id Liggins Institute en
dc.identifier.eissn 1532-2238 en
pubs.record-created-at-source-date 2016-08-18 en
pubs.dimensions-id 27179230 en

Files in this item

Find Full text

This item appears in the following Collection(s)

Show simple item record


Search ResearchSpace